Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00428168Phase 2Terminated

Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment

Role: lead

NCT00409305Phase 2Completed

The Effect of Betahistine on Body Weight in Obese Subjects

Role: lead

NCT01168336Phase 1Completed

Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects

Role: lead

NCT00748436Phase 2Completed

Efficacy Study of Betahistine on Body Weight in Obese Female Subjects

Role: lead

NCT00852956Phase 1Completed

Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects

Role: lead

NCT00466869Phase 2Terminated

A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin

Role: lead

All 6 trials loaded